Log in

Relevant bibliographies by topics / Interleukine-6 [IL-6]

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Interleukine-6 [IL-6]'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Interleukine-6 [IL-6].'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Interleukine-6 [IL-6]"

1

Gaillard, O. "Interleukine 6 (IL-6)." Immuno-analyse & Biologie Spécialisée 17, no. 3 (2002): 140–42. http://dx.doi.org/10.1016/s0923-2532(02)01191-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Abdel-Fattah, M., K. El Gaaly, M. Al-Refai, and D. Galwash. "ESTIMATION OF SALIVARY LEVELS OF INTERLEUKINE-6 (IL-6) AND INTERLEUKINE-8 (IL-8) IN THE ORAL PRE-MALIGNANT AND MALIGNANT LESIONS." Egyptian Dental Journal 62, no. 1 (2016): 193–201. http://dx.doi.org/10.21608/edj.2016.92655.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gorham, Julie, Anthony Moreau, Francis Corazza, et al. "Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis." PLOS ONE 15, no. 12 (2020): e0244628. http://dx.doi.org/10.1371/journal.pone.0244628.

Full text

Abstract:

Introduction Coronavirus disease 2019 (COVID-19) appeared in China in December 2019 and has spread around the world. High Interleukin-6 (IL-6) levels in COVID-19 patients suggest that a cytokine storm may play a major role in the pathophysiology and are considered as a relevant parameter in predicting most severe course of disease. The aim of this study was to assess repeated IL-6 levels in critically ill COVID-19 patients admitted to our Intensive Care Unit (ICU) and to evaluate their relationship with patient’s severity and outcome. Methods We conducted a retrospective study on patients admi

APA, Harvard, Vancouver, ISO, and other styles

4

Kostik, M., M. Makhova, D. Kozlova та ін. "FRI0374 PLASMA LEVELS OF 14-3-3 PROTEIN, S100A8/S100A9-PROTEIN, INTERLEUKIN-6, INTERLEUKIN-18, INTERLEUKIN-4, INTERLEUKIN-17, INTERLEUKIN-1Β AND TUMOR NECROSIS FACTOR-Α IN CHRONIC NON-BACTERIAL OSTEOMYEILITIS AND NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS". Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 784.3–784. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6469.

Full text

Abstract:

Background:Chronic non-bacterial osteomyelitis (CNO) is an immune-mediated disease associated with cytokine dysbalance.Objectives:The aim of our study was to evaluate the cytokines levels in CNO and compare to juvenile idiopathic arthritis (JIA) – disease with immune-mediated mechanism.Methods:The diagnosis of CNO made with criteria, proposed by Jansson (2007, 2009), after the exclusion of other causes of bone disease [1]. We included 42 patients with NBO, 28 patients with non-systemic juvenile idiopathic arthritis (JIA). We evaluated plasma levels of 14-3-3 protein, S100A8/S100A9-protein, int

APA, Harvard, Vancouver, ISO, and other styles

5

Sassano, Pierpaolo, Francesco Paparo, Valerio Ramieri, Walter Colangeli, and Giuseppe Verdino. "Interleukine-6 (IL-6) may be a link between myasthenia gravis and myoepithelioma of the parotid gland." Medical Hypotheses 68, no. 2 (2007): 314–17. http://dx.doi.org/10.1016/j.mehy.2006.06.057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

R. Sarhat, Entedhar, Zubaidah N. M Albarzanji, and Chateen I. Ali Pambuk. "Estimation of Some Interleukins in Cerebrospinal Fluid in Children with Meningitis." Biomedical and Pharmacology Journal 12, no. 04 (2019): 2151–55. http://dx.doi.org/10.13005/bpj/1850.

Full text

Abstract:

Meningitis is often associated with cerebral compromise which may be responsible for neurological squeal in nearly half of the survivors. Little is known about the mechanisms of CNS involvement in bacterial meningitis. the current study was to analyze the clinical significance of cerebrospinal fluid (CSF) concentrations of interleukin (IL)- 6, IL-1, IL-8, IL-10, tumor necrosis factor-alpha (TNF-α), and C-reactive protein in children with meningitis (n=35) and compared with control subjects (n=28). Serum total protein, interleukine-6, IL-1 , IL-8, IL-10 , and, CRP, and TNF-α levels were found t

APA, Harvard, Vancouver, ISO, and other styles

7

Pierer, M., U. Wagner, and S. Unger. "Zytokinblockade zur Behandlung rheumatologischer Erkrankungen." Arthritis und Rheuma 29, no. 04 (2009): 241–42. http://dx.doi.org/10.1055/s-0037-1620175.

Full text

Abstract:

ZusammenfassungDie Interleukine IL-1 und IL-6 sind von elementarer pathogenetischer Bedeutung bei der Entstehung der rheumatoiden Arthritis und damit Angriffspunkte für die Entwicklung neuer Behandlungsstrategien. Die Interleukin-Rezeptor-Antagonisten Anakinra und Tocilizumab dienen neben bzw. bei Versagen der anderen Biologika als Therapieoption mit dem Ziel einer anhaltenden Remission und Verhinderung einer Gelenkdestruktion. Aktu-ell wird in Studien der Einsatz auch bei weiteren entzündlich-rheumatologischen Erkrankungen erprobt. Nach präziser Indikationsstellung, Ausschluss von Kontraindik

APA, Harvard, Vancouver, ISO, and other styles

8

Gantsev, Shamil Kh, and R. R. Bakiyev. "Local tissue interleukine profile in breast cancer." Russian Journal of Oncology 21, no. 1-2 (2016): 60–65. http://dx.doi.org/10.18821/1028-9984-2015-21-1-60-65.

Full text

Abstract:

Breast cancer ranks first in the structure of oncological diseases in women in Russia and in the World. In recent years there have been numerous reports that the growth and progression of breast cancer and other tumors depend not only on their malignant potential, but also on stromal factors presented in the tumor microenvironment and intercellular interactions. The aim of our study was to evaluate intercellular interactions of the tissues surrounding the tumor, by means of determination of the locally interleukine profile. We have identified interleukine profiles of the axillary fatty tissue

APA, Harvard, Vancouver, ISO, and other styles

9

Morieri, Mario Luca, Angelina Passaro, and Giovanni Zuliani. "Interleukin-6 “Trans-Signaling” and Ischemic Vascular Disease: The Important Role of Soluble gp130." Mediators of Inflammation 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/1396398.

Full text

Abstract:

Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset of myocardial infarction. At the same time, IL-6 pathway is divided into two arms: classic signaling (effective in hepatocytes and leukocytes) and trans-signaling (with ubiquitous activity). Trans-signal

APA, Harvard, Vancouver, ISO, and other styles

10

Pieteris, Linas, Giedrė Bakšytė, Tadas Česnaitis, Astra Vitkauskienė, and Andrius Macas. "New strategies in sepsis diagnosis." Acta medica Lituanica 19, no. 3 (2012): 160–62. http://dx.doi.org/10.6001/actamedica.v19i3.2440.

Full text

Abstract:

Successful treatment of sepsis begins from early diagnosis and prognosis. In last decades the number of sepsis cases is growing, so establishing early diagnosis of sepsis as well as effectiveness of treatment are very significant. That is why development of new diagnostic sepsis markers is important. In this review we evaluated a new sepsis marker Presepsin (sCD14) and compared it to other markers: Procalcitonin (PCT), C-reactive protein (CRP) and Interleukine-6 (IL-6).

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Interleukine-6 [IL-6]"

1

Berg, Arjen van den. "Post-transcriptional modulation of IL-6 and IL-8 responses in structural airway cells." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2006. http://dare.uva.nl/document/32479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mansuy, Adeline. "IL-6 tronquée, un antagoniste naturel de l’IL-6 ? : sélection d’un système d’expression : établissement de preuves de concept in vitro : dans les hémopathies malignes et dans les adénocarcinomes du rein." Thesis, Lyon 1, 2009. http://www.theses.fr/2009LYO10337.

Full text

Abstract:

L'interleukine-6 (IL-6) exerce des propriétés biologiques multiples telles que l'activation des cellules immunocompétentes, l'activation de la réponse inflammatoire et l'hématopoïèse. Produite également par les cellules tumorales, l'IL-6 impacte la prolifération, la différenciation et la survie de ces dernières. L'IL-6 représente donc depuis plusieurs années une cible thérapeutique pertinente. Dans la première partie de ce travail, nous avons exploré une nouvelle piste potentielle pour bloquer l'activité biologique de l'IL-6, en utilisant un antagoniste naturel que notre équipe a identifié dan

APA, Harvard, Vancouver, ISO, and other styles

3

Oquendo, Mora Jenny. "Effet du virus de l'hepatite b sur l'expression des genes des cytokines (il-1, il-6, tnf, il-10) in vitro par des lignees mono-lymphocytaires humaines : (thp-1, h9, namalwa)." Paris 11, 1996. http://www.theses.fr/1996PA11T018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Vincent, Thierry. "Recherche de gènes induits par l'interleukine-6 (IL-6) dans des cellules plasmocytaires malignes humaines : induction et fonction du CD44." Montpellier 1, 1999. http://www.theses.fr/1999MON11096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Martineau-Costes, Valérie. "Cytokines de la famille IL-6 et syndecan-1 dans le myélome multiple et le cancer du rein." Montpellier 1, 1998. http://www.theses.fr/1998MON1T015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Alberti, Laurent. "Interleukine 6 et prolifération de l'adénocarcinome du rein : clonage et caractérisation d'une IL-6 tronquée produite par les lignées d'adénocarcinome du rein." Lyon 1, 2002. http://www.theses.fr/2002LYO10187.

Full text

Abstract:

L'adénocarcinome du rein est la septième cause de mortalité par le cancer en France. 25 à 50% des patients présenteront des métastases avec une survie globale à cinq ans de 5%. L'adénocarcinome du rein produit une grande variété de facteurs de croissance et de cytokines contrôlant la prolifération et la dissémination des cellules tumorales, en interagissant entre elles de manière additive, synergique ou antagoniste. Les travaux antérieurs de notre équipe ont montré le rôle central de l'interleukine 6 dans la physiopathologie de cette affection, comme facteur endocrine proinflammatoire et parac

APA, Harvard, Vancouver, ISO, and other styles

7

Gaillard, Jean-Philippe. "Etude structurale et fonctionnelle du récepteur de l'interleukine-6 : interactions moléculaires dans la médiation du message IL-6." Montpellier 2, 1994. http://www.theses.fr/1994MON20275.

Full text

Abstract:

L'interleukine-6 (il-6) est une cytokine multifonctionnelle qui est impliquee comme facteur de croissance dans les proliferations plasmocytaires benignes et malignes. Sa neutralisation a l'aide d'anticorps monoclonaux anti-il-6, entraine le bloquage du clone tumoral chez des patients atteints de myelome multiple (mm). Dans le but d'explorer la possibilite de bloquer le message il-6 en ciblant son recepteur, nous avons produit sept anticorps monoclonaux specifiques de la chaine gp80 du recepteur de l'interleukine-6 (il-6r). Nous avons recherche la fonction des epitopes cibles par nos anticorps.

APA, Harvard, Vancouver, ISO, and other styles

8

Porée, Benoît. "Effets de l'interleukine-6 (IL-6), de son récepteur soluble (sIL-6R) et du facteur de transcription Erg sur l'expression du collagène de type II dans des chondrocytes articulaires." Caen, 2007. http://www.theses.fr/2007CAEN2060.

Full text

Abstract:

Le collagène de type II est un homotrimère de chaînes α1(II) codées par le gène COL2A1. La synthèse de ce marqueur phénotypique du cartilage est fortement altérée lors de l'arthrose. L'IL-6 est une cytokine proinflammatoire nécessitant la coopération du récepteur soluble sIL-6R pour exercer ses effets. Ce mécanisme pallie l'absence totale ou partielle du récepteur membranaire IL-6R dans certains types cellulaires, dont les chondrocytes. Notre étude démontre que l'IL-6 et/ou sIL-6R inhibent la transcription du gène COL2A1 via une région promotrice comprise entre -63 et -35 pb. Cette inhibition

APA, Harvard, Vancouver, ISO, and other styles

9

Szabo-Fresnais, Nicolas. "Dialogues entre les voies de signalisation de l'AMPc et celles de l'IL-1 dans la régulation de l'expression de l'IL-6 et rôle de l'IL-6 dans les thyrocytes et dans les cardiomyocytes." Phd thesis, Université Paris Sud - Paris XI, 2009. http://tel.archives-ouvertes.fr/tel-00451370.

Full text

Abstract:

L'interleukine-6 (IL-6) est une cytokine associée aux maladies auto-immunes de la glande thyroïde et qui pourrait aussi avoir un rôle dans le développement de l'hypertrophie cardiaque pathologique. Dans les cellules thyroïdiennes FRTL-5 et dans les cardiomyocytes de rats adultes, nous montrons que la sécrétion et l'expression de l'ARNm de l'IL-6, stimulées par l'interleukine-1 (IL-1), sont augmentées de manière synergique par la voie de l'AMPc/PKA. Dans les cellules FRTL-5, cet effet synergique s'exerce aussi au niveau de l'activation du promoteur de l'IL-6 et implique les sites AP-1 et CRE ai

APA, Harvard, Vancouver, ISO, and other styles

10

Guillot, Xavier. "Effets thérapeutiques et anti-inflammatoires de la cryothérapie dans les rhumatismes inflammatoires." Thesis, Besançon, 2016. http://www.theses.fr/2016BESA3009/document.

Full text

Abstract:

La cryothérapie est utilisée de manière large et empirique à visée adjuvante dans les rhumatismes inflammatoires, avec un niveau de preuve faible. Dans une revue systématique de la littérature, en poolant les données de 6 études non contrôlées, nous avons pu démontrer que la cryothérapie (locale ou corps entier) appliquée deux fois par jour pendant 7 à 15 jours réduisait significativement l'EVA douleur et le score d'activité DAS25 dans la polyarthrite rhumatoïde. La cryothérapie locale (glace ou gaz froide) montrait par ailleurs des effets taille intra-classes supérieurs à ceux obtenus en util

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Interleukine-6 [IL-6]"

1

Gregory, Bock, Marsh Joan, and Widdows Kate, eds. Polyfunctional cytokines: IL-6 and LIF. Wiley, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Michel, Revel, ed. IL-6: Physiopathology and clinical potentials. Raven Press, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bending, David, Kiran Nistala, and Lucy R. Wedderburn. Pathogenesis of juvenile idiopathic arthritis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0060.

Full text

Abstract:

Although the term juvenile idiopathic arthritis (JIA) encompasses a heterogeneous group of diseases, they all share a common pathological hallmark: inflammation of the synovium. Highly activated T cells, monocytes, and neutrophils are attracted to the joint and secrete mediators that not only perpetuate inflammation but also may attenuate immune regulation. In the oligoarticular and polyarticular forms of JIA, which are thought to be autoimmune conditions, dysregulated adaptive immunity is a likely factor in disease pathogenesis; the nature of the interactions between T effector (Teff) cells a

APA, Harvard, Vancouver, ISO, and other styles

4

Klingenberg, Roland, and Ulf Müller-Ladner. Mechanisms of inflammation. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0270.

Full text

Abstract:

This chapter provides a brief summary of the immune pathogenesis of atherosclerosis, highlighting shared features with inflammatory pathways in rheumatoid arthritis (RA) described in detail in Chapter 25.4. RA constitutes a prototype autoimmune disease primarily affecting the joints but also the heart and vessels associated with increased cardiovascular mortality. Recent years have produced a wealth of novel insights into the diversity of immune cell types which either propagate or dampen inflammation in atherogenesis. Expansion of this inherent anti-inflammatory component carried by regulator

APA, Harvard, Vancouver, ISO, and other styles

5

Gray, Andrew C. Orthopaedic approach to the multiply injured patient. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199550647.003.012003.

Full text

Abstract:

♦ Major trauma results in a systemic stress response proportional to both the degree of initial injury (1st hit) and the subsequent surgical treatment (2nd hit).♦ The key physiological processes of hypoxia, hypovolaemia, metabolic acidosis, fat embolism, coagulation and inflammation operate in synergy during the days after injury/surgery and their effective management determines prognosis.♦ The optimal timing and method of long bone fracture fixation after major trauma remains controversial. Two divergent views exist between definitive early intramedullary fixation and initial external fixatio

APA, Harvard, Vancouver, ISO, and other styles

6

Dasgupta, Bhaskar. Polymyalgia rheumatica. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0134.

Full text

Abstract:

This chapter reviews advances in pathogenesis; European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria with clinical, laboratory, and ultrasound criteria for classification as polymyalgia rheumatica (PMR); the heterogeneity and overlap between PMR, inflammatory arthritis, and large-vessel vasculitis as illustrated by representative cases; recent guidelines on early and correct recognition, investigations, and management of PMR; the scope of disease-modifying agents; socio-economic impact, outcomes, and patient experience in PMR. It also discusses

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Interleukine-6 [IL-6]"

1

Boltz, Marie, Holly Rau, Paula Williams, et al. "Interleukins, -1 (IL-1), -6 (IL-6), -18 (IL-18)." In Encyclopedia of Behavioral Medicine. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rohleder, Nicolas. "Interleukins, -1 (IL-1), -6 (IL-6), -18 (IL-18)." In Encyclopedia of Behavioral Medicine. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Suematsu, S., M. Hibi, T. Sugita, et al. "Interleukin 6 (IL-6) and Its Receptor (IL-6R) in Myeloma/Plasmacytoma." In Current Topics in Microbiology and Immunology. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75889-8_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hautmann, M., E. von Hodenberg, C. Hebbecker, E. Pestel, W. Kübler, and J. Thiery. "Release of interleukin-6 (IL-6) from human vascular smooth muscle cells." In Diätetik und Arteriosklerose. Vieweg+Teubner Verlag, 1993. http://dx.doi.org/10.1007/978-3-663-01942-8_61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Birkmann, Josef, Stefan Rose-John, Manfred Smetak, Thomas Sievert, and Walter M. Gallmeier. "Hyper-IL-6 (H-IL-6), a Fusion Protein of Soluble IL-6 Receptor (Sil-6R), and Interleukin-6 (IL-6), Acts Synergistic with Thrombopoietin (TPO) and Stem Cell Factor (SCF) in Expanding Megakaryocyte Progenitors from Human Cd34++/Cd90+ Cell." In Molecular Biology of Hematopoiesis 6. Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-4797-6_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lohmeyer, J., M. Hadam, N. Kaack, and H. Pralle. "Interleukin-6 (IL-6)/B Cell Stimulatory Factor 2-Dependent Growth of a Human IGA2/к-Myeloma Cell Line." In Cytokines in Hemopoiesis, Oncology, and AIDS. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75510-1_40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tosato, Giovanna, and Sandra E. Pike. "Growth Stimulation and Immunoglobulin (Ig) Secretion in Epstein-Barr Virus (Ebv)-Infected B Cells by Interleukin 6 (IL-6)." In Epstein-Barr Virus and Human Disease • 1988. Humana Press, 1989. http://dx.doi.org/10.1007/978-1-4612-4508-7_34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

"Interleukin 6 (IL-6)." In Dictionary of Rheumatology. Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-79280-3_588.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

KISHIMOTO, T. "Interleukin-6 (IL-6)." In The Cytokine Handbook. Elsevier, 2003. http://dx.doi.org/10.1016/b978-012689663-3/50016-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hassan, Neelam, and Ernest Choy. "Interleukin-6 inhibitors." In Oxford Textbook of Rheumatoid Arthritis. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198831433.003.0032.

Full text

Abstract:

Interleukin 6 (IL-6) is a pleiotropic cytokine which has diverse biological activity, with wide-ranging effects on the immune system, homeostasis, and metabolism. It is the most abundant pro-inflammatory cytokine in the synovial joints and sera of patients with active rheumatoid arthritis (RA) and has been found to play a central role in the pathogenesis of the disease, causing joint inflammation and destruction, as well as systemic manifestations. Inhibition of IL-6 signalling has been investigated and developed as a potential treatment strategy for RA. Clinical trials have demonstrated the efficacy and safety of tocilizumab, a humanized monoclonal antibody directed against the IL-6 receptor, showing therapeutic benefit both in early RA and those considered to have refractory disease. The success of tocilizumab has spurred the development of an array of new biologic agents targeting the IL-6 pathway in RA.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Interleukine-6 [IL-6]"

1

Kura, Yurie, Marco A. De Velasco, Yasuyuki Kobayashi, et al. "Abstract 1226: Interleukin-6 (IL-6) as a therapeutic target in prostate cancer." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Soldo-Jure?a, D., D. Vergles, MI Èulo, and K. Gale?iæ. "AB0012 Urine and plasma interleukin-6 (il-6) levels in patients with glomerular disease." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.811.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lau, Hui Ling, Robert J. J. O'Donoghue, Gary P. Anderson, et al. "Interleukin (IL)-6 And IL-11 Depletion Attenuates Bleomycin-Induced Murine Lung Fibrosis." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5996.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Terai, Mizue, Masumi Eto, Garbo D. Young, et al. "Abstract 1913: Proinflammatory cytokine, Interleukin-6 (IL-6), promotes Interleukin-10 (IL-10) production from melanoma cell via JAK/STAT3 and Raf/ERK signal pathways." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1913.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Andrievskaya, Irina, A. Milovanov, Igor Gorikov, Inna Dovzhikova, and Nataliya Ishutina. "RELATIONSHIP OF INTERLEUKIN-6 AND BLOOD FLOW IN THE UMBILICAL ARTERY DURING EXCERVATION OF MONO- AND MIXT-CYTOMEGALOVIRAL INFECTION IN THE SECOND TRIMESTER OF PREGNANCY." In XIV International Scientific Conference "System Analysis in Medicine". Far Eastern Scientific Center of Physiology and Pathology of Respiration, 2020. http://dx.doi.org/10.12737/conferencearticle_5fe01d9c664388.47461710.

Full text

Abstract:

In order to determine the role of a cytokine in the regulation of blood supply to the placenta, the relationship between interleukin-6 (IL-6) in serum and blood flow in the umbilical artery in healthy pregnant women and during pregnancy complicated by exacerbation of mono- and mixed cytomegalovirus infection in the second trimester was studied

APA, Harvard, Vancouver, ISO, and other styles

6

DiTullio, A. E., S. Park, P. A. Torzilli, and C. T. Chen. "Cyclic Compression of Chondrocytes Counteracts Pro-Inflammatory Tissue Remodeling Induced by Interleukin-1." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193027.

Full text

Abstract:

Chondrocytes in tissue engineered constructs face challenging environments when first transplanted into a synovial joint, including high levels of compression/shear and pro-inflammatory cytokines. The joint level of interleukin 1 (IL-1) after trauma injury and in a repaired joint is acutely elevated. Matrix remodeling in tissue engineered constructs can be easily affected by the elevation and activation of aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases (MMPs) [2–4, 7–9, 11]. Several recent studies suggest that tensile loading and unconfined compression of chondrocytes has s

APA, Harvard, Vancouver, ISO, and other styles

7

Chen, C. T., S. Park, M. Bhargava, and P. A. Torzilli. "Inhibitory Effect of Mechanical Load on IL-1 Induced Cartilage Degradation Is Mediated by Interferon-Gamma and IL-1 Receptor 1." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193230.

Full text

Abstract:

Matrix remodeling in articular cartilage is regulated by the elevation and activation of aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases (MMPs) [2–4, 7–9, 10]. Several recent studies from our and other groups have shown that mechanical loading can counteract interleukin 1 (IL-1) induced pro-inflammatory and catabolic events by down-regulating aggrecanases, MMPs, and pro-inflammatory genes [1, 3, 5, 6], but the molecular mechanism is not clear. Many previous studies have shown that the regulation of pro-inflammatory effect of IL-1 come from several aspects: anti-inflammatory

APA, Harvard, Vancouver, ISO, and other styles

8

Agus Faizal, Imam, Agung Dwi Wahyu Widodo, and Jusak Nugraha. "The Effect of Macrophage Dose to Secretion Interleukin 6 (IL-6) on Model of Tuberculosis Granuloma In Vitro." In 2nd International Conference Postgraduate School. SCITEPRESS - Science and Technology Publications, 2018. http://dx.doi.org/10.5220/0007541803060311.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ekshyyan, Oleksandr Y., Xiaohua Rong, Tara Moore-Medlin, Xiaohui Ma, Jonathan Steven Alexander, and Cherie-Ann O. Nathan. "Abstract 4044: Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Shimp, Samuel K., Christopher M. Reilly, and Marissa Nichole Rylander. "Empirical Modeling the Effect of Hsp90 Inhibition on Cytokines Associated With Impaired Biotransport of Apoptotic Debris." In ASME 2010 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2010. http://dx.doi.org/10.1115/sbc2010-19572.

Full text

Abstract:

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disorder that can affect nearly every organ in the body. A link has been established between abnormal biotransport of apoptotic cell debris and pathogenesis of SLE [1]. Lupus mice are hyper-responsive to immune stimulation and overproduce inflammatory mediators including IL-6, IL-12, and nitric oxide (NO) [2]. Extracellular expression and transport of inflammatory cytokines are thought to be involved with the inhibited clearance of cellular debris [1]. Hsp90 has a prominent role in folding and conformational regulation of

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Interleukine-6 [IL-6]"

1

Morris, Andrew M., Sally Bean, Chaim M. Bell, et al. Strategies to Manage Tocilizumab Supply During the COVID-19 Pandemic. Ontario COVID-19 Science Advisory Table, 2021. http://dx.doi.org/10.47326/ocsat.2021.02.22.1.0.

Full text

Abstract:

Tocilizumab is an anti-inflammatory medication that acts by inhibiting interleukin-6 (IL-6) and is shown to improve outcomes including mortality in patients hospitalized with COVID-19 requiring supplemental oxygen. Ontario supply of tocilizumab is limited, and tocilizumab demand in Ontario might exceed supply in the near future. A strategy that includes using a fixed, single intravenous dose of 400 mg for eligible patients will help extend available supply and is likely effective in treatment of COVID-19. Sarilumab, another IL-6 inhibitor, can be considered as a substitute. Additional options

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!